The fourth test for which the firm has received regulatory clearance this year takes aim at a common microbial cause of healthcare-associated infections.
The firm's real-time PCR assay for rapid detection and differentiation of novovirus genogroup I and II runs on the Aries sample-to-answer system.
The firm will encounter stiff competition, particularly from BioMérieux and Luminex, but there are untapped opportunities for adoption, according to industry analysts.
The real-time PCR, sample-to-answer assay provides surveillance of whooping cough, a contagious respiratory disease, in clinically symptomatic patients.
Assay revenues rose 38 percent to $37.4 million and infectious disease sales made up about 82 percent of the firm's total Q1 assay sales.
Applied Biocode intends to have panel for identifying 18 gastrointestinal pathogens on the clinical market by the end of the year.
The GenomeWeb Index rose nearly 5 percent in February, on par with the Dow and slightly outperforming the Nasdaq.
The firm reported that revenues for Nanosphere, which Luminex acquired in 2016, were up 39 percent year-over-year.
The bank rated companies like Thermo Fisher Scientific and Agilent at Buy, Illumina and PerkinElmer at Hold, and Myriad Genetics and Luminex at Sell.
Executives from Luminex and Exact Sciences provided updates on their companies at the 35th Annual JP Morgan Healthcare Conference in San Francisco.
Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.
The New York Times reports that a number of companies and research institutes are pursuing gene therapies.
Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.
In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.